Vietnam is rapidly strengthening its position in genomics and precision medicine, creating significant opportunities for gene expression analysis technologies across healthcare, pharmaceutical research and biotechnology.
While Vietnam-specific market figures are not yet widely published, industry analysis estimates the country's gene expression analysis market is currently valued at US$14–20 million in 2025 and is projected to reach US$28–40 million by 2030. The market is expected to outpace global growth as Vietnam increases investment in molecular diagnostics, cancer research and personalised healthcare.
The opportunity reflects a rapidly expanding global market. According to IMARC Group, the global gene expression analysis market was valued at US$6.0 billion in 2025 and is forecast to reach US$12.1 billion by 2034, growing at a CAGR of 7.9%. Increasing adoption of genomics, advances in sequencing technologies and growing demand for biomarker discovery are driving investment worldwide. (imarcgroup.com)
Vietnam's growth is being fuelled by several long-term trends:
- Expansion of precision medicine and personalised healthcare programmes.
- Rising incidence of cancer and increasing use of molecular profiling in oncology.
- Growing investment in pharmaceutical and biotechnology research and development.
- Wider adoption of RNA sequencing (RNA-Seq), quantitative PCR (qPCR) and next-generation sequencing (NGS).
- Increasing collaboration between Vietnamese research institutes and international life sciences organisations.
- Falling sequencing costs making advanced genomic testing more accessible. (imarcgroup.com)
Gene expression analysis enables researchers and clinicians to measure how genes are activated or suppressed in different cells and tissues, providing critical insights into disease mechanisms, treatment response and biomarker identification. The technology has become an essential tool in cancer diagnostics, drug discovery, pharmacogenomics, infectious disease research and translational medicine.
The market is also benefiting from the rapid expansion of Vietnam's molecular diagnostics sector. IMARC Group estimates that the country's molecular diagnostics market reached approximately US$108.9 million in 2024 and is projected to grow to US$195.4 million by 2033, providing a strong foundation for broader adoption of advanced genomic technologies. (imarcgroup.com)
Leading life science companies including Thermo Fisher Scientific, Illumina, Agilent Technologies, Bio-Rad Laboratories, QIAGEN, Roche, BGI Genomics, Pacific Biosciences and Revvity continue to invest in next-generation platforms that combine high-throughput sequencing, advanced bioinformatics and artificial intelligence to support precision medicine and biomedical research.
As Vietnam continues to expand its biotechnology capabilities and modernise its healthcare system, gene expression analysis is expected to become an increasingly important component of clinical diagnostics, pharmaceutical innovation and genomic research. For suppliers of genomics technologies, molecular diagnostics, laboratory instrumentation and bioinformatics solutions, Vietnam represents one of Southeast Asia's most promising emerging growth markets.